Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether there is a benefit to giving a dopamine agonist to a patient with Parkinson's disease who is already being treated with levodopa.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Boehringer Ingelheim
• Treatments: Dopamine; Dopamine Agents; Dopamine Agonists; Levodopa; Pramipexole

Criteria

Inclusion Criteria:

• Age 30-80

• Idiopathic PD Hoehn & Yahr stage 2-4,

• diagnosed by 2 of the 3 cardinal motor features

• Fluctuation response to levodopa

• Dyskinesia

• No other historical, laboratory or physical signs to suggest an alternate diagnosis

• No significant dementia, MMSE>24

• On oral levodopa therapy

Exclusion Criteria:

• dementia

• psychosis

• severe anxiety

• unstable cardiovascular disease

• uncontrolled hypertension

• history of cardiac arrhythmias

• active peptic ulcer disease

• anemia (HCT<32%)